Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Aging (Albany NY). 2024 Jun 11;16(11):10074-10107. doi: 10.18632/aging.205921.
SMARCD3 has recently been shown to be an important gene affecting cancer, playing an important role in medulloblastoma and pancreatic ductal adenocarcinoma. Therefore, we conducted this research to investigate the potential involvement of SMARCD3 across cancers and to offer recommendations for future studies.
Utilizing information on 33 malignancies in the UCSC Xena database, SMARCD3 expression and its prognostic value were assessed. The tumor microenvironment was evaluated with the "CIBERSORT" and "ESTIMATE" algorithms. SMARCD3 and immune-related genes were analyzed using the TISIDB website. The pathways related to the target genes were examined using GSEA. MSI (microsatellite instability), TMB (tumor mutational burden), and immunotherapy analysis were used to evaluate the impact of target genes on the response to immunotherapy.
There is heterogeneity in terms of the expression and prognostic value of SMARCD3 among various cancers, but it is a risk factor for many cancers including uterine corpus endometrial cancer (UCEC), renal clear cell carcinoma (KIRC), and gastric adenocarcinoma (STAD). GSEA revealed that SMARCD3 is related to chromatin remodeling and transcriptional activation, lipid metabolism, and the activities of various immune cells. The TMB and MSI analyses suggested that SMARCD3 affects the immune response efficiency of KIRC, LUAD and STAD. Immunotherapy analysis suggested that SMARCD3 may be a potential immunotherapy target. RT-qPCR demonstrated the variation in SMARCD3 expression in KIRC, LUAD, and STAD.
Our study revealed that SMARCD3 affects the prognosis and immunotherapy response of some tumors, providing a direction for further research on this gene.
SMARCD3 最近被证明是影响癌症的重要基因，在髓母细胞瘤和胰腺导管腺癌中发挥重要作用。因此，我们进行了这项研究，以调查 SMARCD3 在各种癌症中的潜在作用，并为未来的研究提供建议。
利用 UCSC Xena 数据库中 33 种恶性肿瘤的信息，评估 SMARCD3 的表达及其预后价值。使用“CIBERSORT”和“ESTIMATE”算法评估肿瘤微环境。使用 TISIDB 网站分析 SMARCD3 和免疫相关基因。使用 GSEA 检查与靶基因相关的通路。MSI（微卫星不稳定性）、TMB（肿瘤突变负荷）和免疫治疗分析用于评估靶基因对免疫治疗反应的影响。
SMARCD3 在各种癌症中的表达和预后价值存在异质性，但它是包括子宫体子宫内膜癌（UCEC）、肾透明细胞癌（KIRC）和胃腺癌（STAD）在内的许多癌症的危险因素。GSEA 表明 SMARCD3 与染色质重塑和转录激活、脂质代谢以及各种免疫细胞的活性有关。TMB 和 MSI 分析表明，SMARCD3 影响 KIRC、LUAD 和 STAD 的免疫反应效率。免疫治疗分析表明，SMARCD3 可能是一个潜在的免疫治疗靶点。RT-qPCR 显示了 KIRC、LUAD 和 STAD 中 SMARCD3 表达的变化。
我们的研究表明，SMARCD3 影响某些肿瘤的预后和免疫治疗反应，为进一步研究该基因提供了方向。
